Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Speculating, but maybe it's due to patients who are taking BCPs and smoke?
It's unlikely to matter anyway, as patients will prefer to have fewer injections and will likely pay the same or even more to do so.
That's frustrating about the negative PCR. If a person has flu-like symptoms and tests negative for Covid and also for the flu, I think it's best practice to assume that patient has Covid, especially if a person has acute loss of taste or smell. So, to answer your question, while I believe in the rapid test (and especially the PCR test), in today's climate, I would favor a symptom-based approach if the tests are negative when everything else is screaming Covid.
I'm no pro when it comes to the ins and outs of Covid testing with regards to false negatives and false positives, but what we were told was a person is more likely to get a false negative from the rapid (antigen) test if they have no symptoms. That might stand to reason that it might give a false negative early on or later in the disease for that same reason, but that's just an educated guess.
On a separate note, if a person has symptoms and still tests negative with the rapid, they should be getting the PCR for follow-up. Likewise, people with significant exposures that test negative on rapid should also have confirmatory PCR testing. Symptomatic patients that test positive on rapid are not routinely being followed up with PCR b/c rapid test false positives in symptomatic patients is less likely.
P.S. Glad to hear your case was mild.
Thank you very much. Fingers crossed.
That's good news that nobody else tested positive. The younger people tend to have little to no symptoms, so that makes sense the kid only had a headache. It is crazy how nobody else got it, despite how easily it's transmitted. My cousin's son got it (he only had loss of smell and taste), and he didn't spread it to anybody else somehow either. He's 20 y/o, I think, and was home from college for the summer when he got it.
As an aside, I just tested positive for it, too. I'm an interventional radiology PA, and I've been doing procedures on Covid patients since March. On Thursday at work I had a slight cough throughout the day and a little low back pain. When I got home that evening I also had some chest pain. It started making me nervous that maybe I actually had Covid.
Then later that night I found out that my coworker tested positive for Covid-19. We have been getting tested weekly at work for probably the last five weeks due to our high risk since we do procedures on inpatients (including a fair number of Covid+ pts) and outpatients. My test was performed the same day as my coworker's on Thursday; but when I took mine I had the slower PCR test, and she had the rapid test when she took hers later in the day.
Once I found that her positive results, I got really nervous that my symptoms were truly consistent with Covid-19. Then, I was up for good at 2:00am with fever of 102.7, chills, body aches, really bad headache, mild cough, mild intermittent chest pain, and bilateral hip pain. The headache has persisted on and off and was probably the worst thing other than the fever/chills.
My test came back last night, unsurprisingly, as positive. Hopefully nobody else in my house will get it. I am isolating.
I'm really frustrated because I took such good caution in and out of work to avoid getting it, then I have to get the virus the week before I was supposed to get my vaccine.
My coworker and I were exposed to a patient during a procedure on 12/2 who wasn't known to have Covid-19 at the time. She had hepatic encephalopathy and she kept taking her mask off and coughing. We just had regular masks on (not N95s) because she was initially negative. She tested positive shortly after. We were informed through contact tracing that we were at risk, but I figured I'd still be ok given that I'd made it this far after basically swimming in Covid for quite a while. Guess not.
Long story short, the virus is unpredictable as far as transmission. The better we are at protecting ourselves, the better off we are!
The rapid test can have false negatives and false positives. The PCR test is the gold standard and the confirmatory test. The son could have had a confirmatory PCR test, but it's not generally done...so it's not surprising that they didn't test him with the PCR. There are more false negatives than false positives with the rapid test. Maybe that's what she was referring to.
I never thought I'd see a post on this forum regarding superpositions and the collapse of a wave function, yet here we are :) As a physics aficionado, I ABSOLUTELY love this post!
You're back!!
Looks like highly statistically significant results. One interesting note is:
Median duration of effect was 24.0 and 20.3 weeks, for the 125 Unit and 250 Unit dose groups respectively, based on the median time to loss of 80% of the peak treatment effect.
I would have thought the higher dose would have led to better median duration of effect.
I'd have to go back and look at the phase 2 results to compare, but I can't do that right this second.
"blemish-free"...Clever. I see what you did there.
Priced at $13
It could be a necessary evil to make way for possible RVNC acquisition.
Nestlé should be saving it's money for RVNC. EOM.
Continuing along with the Spanish theme (and cosmetic-centric name): Semiaño...as in twice a year ;)
Duratox. Great name!! Let it be so! Daxi, is also quite fine. I agree, I don't think they need to come up with separate names for cosmetic or therapeutic indications.
I gave it a little though today and came up with some possible names. It's a more challenging exercise than I would have imagined at first. I'm glad I don't have to make the final decision like the people at Revance.
Bonita or bonito (Spanish for pretty, not to be confused with Boniva)
Hermosa or hermoso (Spanish for beautiful)
Juventud (Spanish for youth, but too close in spelling to Jeuveau, IMO, even though, phonetically, they aren't too close). I don't know why I kept thinking of Spanish words for names.
Glamify
Nextgentox
Panash (play on "panache")
Panacea (since botulinum toxin has so many uses and potential other uses).
Yes, I thought there would be a better name chosen as well. They still have a chance to come up with something clever for cosmetic indications then.
"Daxxify. It's about time."
Here's another patent they filed for:
https://uspto.report/TM/90128805
I am being very conservative, but I came up with that number based on projected $1B revenue once daxi is up and running and applying a multiplier of 7. Keep in mind Dysport was doing around $500M annualized at one point. My figure doesn't even account for their cash hoard, their filler line, and projections for off-label use. I'm just applying a discount because of the uncertainty surrounding a company's launching of a new product, particularly against a product like Botox that has a moat around it -- and the relative uncertainty of FDA's labeling, whether it gives RVNC the six-month duration it deserves.
If true, it should be for one of the biggest premiums in your running list of buyouts of publicly traded companies. They would be fools to sell for anything less than $7B. I think they can get there organically on their own in short order if things pan out as expected over the next half year and into daxi launch.
Gotcha. I didn't see that in the transcripts. To bad, it would have been a cool name!
Looks like RVNC filed a few patent applications
PREVU
https://uspto.report/TM/90106769
REVANCEU
https://uspto.report/TM/90106803
REVANCEU STUDIO
https://uspto.report/TM/90106821
If "Prevu" is the proposed name for daxi, I really like it. I can see a slogan being "Prevu the new you."
WHO official walks back comments on asymptomatic transmission being 'very rare'
https://news.yahoo.com/official-walks-back-comments-asymptomatic-160348795.html
You make good points. The acquisition cost is high given HintMD's $1.5mill revenue in 2019, but that revenue should help offset IT-related costs. I don't think it's a foregone conclusion that this platform will only be for RVNC now. Part of their rationale for buying was to gain the fees collected through the service. I think that while the cost is steep, Revance has their eyes set on the bigger prize...stealing away market share from AGN/ABBV. They needed to get a system like this that provides them with the tools they need, especially the loyalty program and subscription services. I do agree that they could have just used that service (rather than owning it), but they must see the forest through the trees and have good reasons for making an all-out acquisition.
I think that's why they brought them into the fold because RVNC doesn't have that level of expertise, but HintMD does. The acquisition gives them access to up-and-running payment option, subscription service, loyalty program, analytics, etc. The HintMD CEO will be joining RVNC BoD to provide the necessary insight as well.
I would agree that there is a significant number of Covid-19 patients getting renal failure. We are placing a fair number of dialysis catheters in these patients in the ICU at a Connecticut hospital that I work at.
That is great information. I'm an interventional radiology physician assistant, doing procedures on +Covid-19 patients. The notes your physician friend made about CT scan of chest for rule out PE protocol was interesting...as well as his indicators for worse prognosis. Thanks for posting. Good luck to him and all of you on this board.
NVAX - Just fyi: it's not FDA approved yet...it just had a successful Ph3 trial.
All good points. Interesting times we are living in right now. Hopefully it turns out to be a shrewd move...much like RVNC's timing of a secondary and then their convertible notes shortly thereafter.
VKTK - to buy back $50mil worth of its shares
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=114883719&type=HTML&symbol=VKTX&companyName=Viking+Therapeutics+Inc.&formType=8-K&dateFiled=2020-03-17&CK=1607678
Odd, coming from pre-commercialization biopharmaceutical...but I guess they see value in repurchasing their stock with the market being so hammered down.
Re: Coronavirus and spring/summer
That's what I was hoping since winter seems about over in the Northeast where I live, but I read an article a few days ago that seemed not to support that view:
https://www.scmp.com/news/china/science/article/3074970/coronavirus-becomes-pandemic-scientists-ask-if-lines-map-hold
Having known what we know now re dermal fillers, I would have loved to hear Foley's internal thoughts when this dialogue was going on during last quarter's conference call:
Operator
Thank you. Our next question comes from the line of Tim Lugo with William Blair. Your line is now open.
Tim Lugo
Thanks for taking my question and congratulations on what seems like a smooth transition. Maybe from a higher view DAXI is obviously coming to market with differentiated product. However, it still is only one product, how do you currently view the bundle that you would be competing against and just marketing against that suite of products from a larger competitor and also your larger competitor is obviously having some transition of its own. So can you talk maybe if you're hearing about anything from the sales force disturbances or anything from that transition which could be beneficial for that launched?
Mark Foley
I mean it's great question. I think because we have a product that is so unique and so differentiated I think it's certainly possible to have a successful commercial launch in aesthetics without any other products in the bundle and I think that certainly physicians will have alternative choices in other products in the bundle, certainly we seen with recent competitive entrance that with a single neuromodulator that they been able to successfully generate physician interest and patient interested in trying the product. So we don't believe that we need other products to be successful in the market because of our value proposition. Having said that we will continue to be mindful and if there are things along the way that we think can contribute to our success, create efficiencies, create more compelling offer for either the position of the consumer, we will of course continue to look at that. But I think right now we feel pretty good about how were able to launch it.
Looks like a race to the bottom...
https://www.businesswire.com/news/home/20191001006211/en/TD-Ameritrade-Introduces-0-Commissions-Online-Stock
Technically, Fall ends December 21st.
Re plant-based "meat" products
I subscribe to "SciShow" YouTube channel, as well its daughter channel called "SciShow Space" (well worth looking into if you haven't already). Anyway, this SciShow video explains some of the science behind the meatless products you guys have been discussing on this board.
I think they are grossly underestimating RVNC's sales in 2024. They also had a typo in the fourth-to-last paragraph, calling RT002 "RT001."
Thanks for the reply. Also, your reply in msg-148998063, which referenced msg-136697136 in 2017, was helpful because I vaguely remembered reading on this board an opinion about the presumed need for divestiture of Dysport prior to a RVNC takeover. Thanks for finding that reference.
I just realized my post after yours asked similar question. I thought I had pressed "send" on my post almost an hour ago, but it never went through. So when I finally sent it, I checked for new posts and saw yours with similar question...